Health & Fitness
Health and Fitness
Health and Fitness 
Mon, December 8, 2008
Sun, December 7, 2008
ARIAD To Hold Conference Call on Monday Morning, December 8, 2008
CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) will hold an investor conference call at 8:30 a.m. (ET) on Monday, December 8, 2008 to discuss recent resignations from its Board of Directors and to provide an update on progress in the Company's programs. Harvey J. Berger, M.D., chairman and chief executive officer, will host the call.
The live webcast can be accessed by visiting the investor relations section of the Company's website at [ http://www.ariad.com/investor ]. The call can be accessed by dialing (866) 831-6291 (domestic) or (617) 213-8860 (international) five minutes prior to the start time and providing the passcode 72759761. A replay of the call will be available on the ARIAD website approximately two hours after completion of the call and will be archived for two weeks.
About ARIAD
ARIAD is engaged in the discovery and development of breakthrough medicines to treat cancer by regulating cell signaling with small molecules. ARIAD is developing a comprehensive approach to patients with cancer that addresses the greatest medical need - aggressive and advanced-stage cancers for which current treatments are inadequate. ARIAD has a global partnership with Merck & Co., Inc. to develop and commercialize deforolimus, ARIAD's lead cancer product candidate, which is in Phase 3 clinical development. ARIAD's second oncology product candidate, oral AP24534, is a novel multi-targeted kinase inhibitor in Phase 1 clinical development in hematological cancers. ARIAD has an exclusive license to pioneering technology and patents related to certain NF-κB treatment methods, and the discovery and development of drugs to regulate NF-κB cell-signaling activity, which may be useful in treating certain diseases. Additional information about ARIAD can be found on the web at [ http://www.ariad.com ].